Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) – Analysts at B. Riley issued their FY2017 earnings estimates for shares of Asterias Biotherapeutics in a research note issued on Thursday. B. Riley analyst G. Zavoico forecasts that the biotechnology company will post earnings per share of ($0.62) for the year. B. Riley currently has a “Buy” rating and a $6.00 target price on the stock. B. Riley also issued estimates for Asterias Biotherapeutics’ Q4 2017 earnings at ($0.18) EPS, Q1 2018 earnings at ($0.16) EPS, Q2 2018 earnings at ($0.15) EPS, Q3 2018 earnings at ($0.16) EPS, Q4 2018 earnings at ($0.17) EPS, FY2018 earnings at ($0.64) EPS, FY2019 earnings at ($0.66) EPS, FY2020 earnings at ($0.70) EPS, FY2021 earnings at ($0.75) EPS and FY2022 earnings at ($0.19) EPS.
Several other analysts have also recently issued reports on AST. Zacks Investment Research cut shares of Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 22nd. HC Wainwright restated a “buy” rating on shares of Asterias Biotherapeutics in a research report on Wednesday, November 22nd. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $8.35.
A number of institutional investors have recently bought and sold shares of AST. Millennium Management LLC purchased a new stake in Asterias Biotherapeutics in the 4th quarter worth about $132,000. Virtu Financial LLC raised its position in Asterias Biotherapeutics by 387.0% in the 4th quarter. Virtu Financial LLC now owns 71,588 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 56,888 shares during the period. Finally, Deutsche Bank AG raised its position in Asterias Biotherapeutics by 110.5% in the 4th quarter. Deutsche Bank AG now owns 66,180 shares of the biotechnology company’s stock worth $148,000 after purchasing an additional 34,739 shares during the period.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.